Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.37 -0.79 (-0.59%)
Streaming Delayed Price Updated: 12:07 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs. 
Via The Motley Fool
Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments. 
Via The Motley Fool
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now. 
Via InvestorPlace
Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.
Novo Nordisk's Wegovy recently gained Food and Drug Administration approval to reduce the risk of cardiovascular problems. 
Via Investor's Business Daily
Decoding 7 Analyst Evaluations For Novo Nordisk
Via Benzinga
Is Novo Nordisk on the Verge of Another Blockbuster Drug?
Novo Nordisk just received some positive news for its latest obesity drug, amycretin. 
Via The Motley Fool
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is NYSE:NVO suited for dividend investing?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for dividend investing? 
Via Chartmill
Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health
Medicare considers extending coverage for Novo Nordisk's Wegovy to eligible members with heart disease history. CMS may include anti-obesity drugs under certain Medicare Part D plans. Germany's health... 
Via Benzinga
7 Stocks That Are Creating a Buzz on Wall Street
Buy these stocks creating buzz in order to inject some green into your portfolio and give your investment returns a boost. 
Via InvestorPlace
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
Has Novo Nordisk's already red-hot stock become an even better buy? 
Via The Motley Fool
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years. 
Via Benzinga
3 Biopharma Stocks Predicted to Soar in Q2 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals. 
Via InvestorPlace
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
The company continues to impress investors. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk Stock Stalls On Oprah TV Special, But Reddit Traders Believe It's 'Not Done Yet'
Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk, weight-loss drug Ozempic and talk show host Oprah Winfrey. 
Via Benzinga
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
The gap has been shrinking between these stocks over the past month. 
Via The Motley Fool
Tesla Investor Ross Gerber Backs Ozempic's Potential To Reduce Monthly Food Expenses — Less Eating, More Saving
Ross Gerber, a prominent Tesla investor, has suggested that the use of Ozempic could lead to significant cost savings. 
Via Benzinga
3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50
These dividend stocks selling for under $50 with yields of 5% or more offer a lot to investors at any time making these strong buys. 
Via InvestorPlace
What Retail Apocalypse? 7 Stocks Proving the Doomsayers Wrong.
People have said retail is dying for years now but the supposed apocalypse is nowhere to be found with these fast-charging retail stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Did Novo Nordisk Just Get a Jump on Eli Lilly?
A recent FDA announcement may have just put one company in the lead. 
Via The Motley Fool
Exposures Product Safety
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
Winfrey dedicated a prime-time special to discussing the stigma surrounding weight loss and the use of drugs like Ozempic and Mounjaro 
Via Benzinga
LifeMD Shares Come Back to Life on GLP-1 Business Growth
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024 
Via MarketBeat
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
Exposures Product Safety
Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits
Debate ensues over insurance coverage for Novo Nordisk's Wegovy following FDA approval. Evernorth's EncircleRx introduces financial guarantee, aiming to control costs and improve accessibility.... 
Via Benzinga
Exposures Product Safety
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
Latest in weight-loss medication trends: Eli Lilly And Co's Zepbound (tirzepatide) surges past rival Novo Nordisk A/S's Wegovy (semaglutide) in new prescriptions, signaling a shift in the obesity... 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Exhibits Quality Stock Traits. Here's Why.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) should be investigated by quality investors. 
Via Chartmill
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
The drugmaker is magnificent in its own right. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.